Comparative Pharmacology
Head-to-head clinical analysis: ATENOLOL versus BETAGAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATENOLOL versus BETAGAN.
ATENOLOL vs BETAGAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects.
Beta-1 selective beta-adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
50 mg orally once daily; may increase to 100 mg orally once daily if needed.
Instill 1 drop of 0.25% or 0.5% solution into the affected eye(s) twice daily.
None Documented
None Documented
6-9 hours (terminal elimination half-life); may increase to 15-30 hours in renal impairment (CrCl <35 mL/min).
Clinical Note
moderateAtenolol + Digoxin
"Atenolol may increase the bradycardic activities of Digoxin."
Clinical Note
moderateAtenolol + Digitoxin
"Atenolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateAtenolol + Deslanoside
"Atenolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateAtenolol + Acetyldigitoxin
"Atenolol may increase the bradycardic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 10-15 hours in adults; prolonged in renal impairment (up to 30 hours).
Renal: 40-50% unchanged drug; minor hepatic metabolism (10-20%) with biliary excretion of metabolites; <5% fecal.
Primarily renal excretion of unchanged drug and metabolites; about 80% eliminated in urine, 20% in feces as unchanged drug or glucuronide conjugates.
Category C
Category C
Beta-Blocker
Beta-Blocker